Research Cluster
Skin, Cosmetic & Pigmentation Peptides
This cluster spans the widest evidence range on the site: from hydrolyzed collagen peptides with multiple randomized controlled trials in the published literature to injectable compounds with no human data at all. It also contains some of the highest-traffic search terms in peptide research—which means it is also where marketing claims most reliably outrun the science.
Route of administration is the critical variable throughout this cluster. Several compounds with legitimate human data in topical or oral applications—GHK-Cu, collagen peptides, argireline, matrixyl—are increasingly discussed and used in injectable form, for which the evidence base does not exist. That distinction is applied consistently across every compound card on this page.
Cluster at a Glance
12 compounds • 1 FDA-approved • 1 with strong RCT data • 4 pilot/limited human data • 3 It’s Complicated • 3 preclinical only
Approved Drug
Clinical Trials
Pilot / Human Data
It’s Complicated
Preclinical Only
Editorial note: This cluster spans from FDA-approved drugs with Phase III data to preclinical-only compounds with no human trials. Evidence tiers are applied strictly—a compound’s popularity in skincare marketing has no bearing on its tier placement. Read the tier badge on each card before the claims.
Acetyl Tetrapeptide-5 (Eyeseryl): What the Research Actually Shows
Periorbital anti-edema peptide targeting capillary permeability reduction and anti-glycation. Only Cluster G compound addressing under-eye puffiness specifically. Lipotec-sponsored study of 20 women reports 70% puffiness reduction at 5% topical. Periorbital injection carries serious anatomical risk.
Read the research →
AHK-Cu (Copper Tripeptide-2): What the Research Actually Shows
Synthetic copper-chelating tripeptide (Ala-His-Lys + Cu²⁺). Related to but distinct from GHK-Cu — different sequence, different evidence base, no published human clinical trials. In vitro collagen stimulation and wound healing data. Frequently confused with GHK-Cu; evidence does not transfer between compounds.
Read the research →
Argireline (Acetyl Hexapeptide-3): What the Research Actually Shows
SNARE complex inhibitor studied for topical wrinkle reduction. Small manufacturer-sponsored clinical trials at 5–10% show modest effects. Evidence does not support "Botox in a bottle" claims.
Read the research →
Copper Peptides for Hair: GHK-Cu vs AHK-Cu
GHK-Cu and AHK-Cu—copper-binding tripeptides with distinct mechanisms. GHK-Cu has topical human data from wound healing and skin contexts; hair-specific clinical evidence is limited to cosmetic-use observations.
Read the research →
Leuphasyl (Pentapeptide-18): What the Research Actually Shows
Stabilized enkephalin analog (Tyr-D-Ala-Gly-Phe-Leu) targeting opioid receptors on motor nerve terminals to reduce NMJ excitability. Mechanistically independent from and non-competing with argireline. No standalone clinical evidence — all human data from argireline combination study only.
Read the research →
Matrixyl (Palmitoyl Pentapeptide-4): What the Research Actually Shows
The original palmitoylated matrikine peptide. Largest clinical study in the Cluster G group — 93 women, 6 months, retinol comparator. Distinct from Matrixyl 3000. Collagen I/III stimulation via KTTKS procollagen fragment signal.
Read the research →
Matrixyl 3000: What the Research Actually Shows
Combination of palmitoyl tripeptide-1 (collagen-stimulating matrikine) and palmitoyl tetrapeptide-7 (anti-inflammatory). Small manufacturer-associated clinical trials support modest wrinkle-reducing effects at 2–5% topical concentration.
Read the research →
Palmitoyl Hexapeptide-12: What the Research Actually Shows
Palmitoylated elastin-derived hexapeptide (Pal-VGVAPG) proposed to inhibit NMJ acetylcholine release. Weakest evidence position in Cluster G — no published clinical trials, no PubMed-indexed mechanistic studies for NMJ activity, molecular target uncharacterized in public literature.
Read the research →
Palmitoyl Tetrapeptide-7 (Rigin): What the Research Actually Shows
Anti-inflammatory component of Matrixyl 3000. IgG-derived Pal-GQPR sequence suppresses IL-6 and cytokine-driven MMP activity in keratinocytes. Targets inflammaging — the collagen degradation side of skin aging. Distinct mechanism from collagen-stimulating peptides.
Read the research →
Palmitoyl Tripeptide-1: What the Research Actually Shows
GHK matrikine component of Matrixyl 3000. Stimulates collagen I/III and fibronectin via TGF-β pathway. Distinct from GHK-Cu — no copper chelation. Clinical evidence primarily from Matrixyl 3000 combination studies; strong independent mechanistic foundation.
Read the research →
Snap-8 (Acetyl Octapeptide-3): What the Research Actually Shows
Extended SNARE complex inhibitor — argireline with two additional C-terminal residues. Greater in vitro binding affinity than argireline but higher molecular weight (1,075 Da) and weaker published evidence. Clinical data in manufacturer documentation only — not published as standalone peer-reviewed article.
Read the research →
Syn-Ake: What the Research Actually Shows
Synthetic analog of waglerin-1 (Temple Viper venom peptide). Postsynaptic nAChR antagonist targeting facial muscle contraction. One manufacturer-sponsored study at 4% topical concentration. Mechanistically distinct from and complementary to Argireline.
Read the research →
Tripeptide-29: What the Research Actually Shows
Gly-Pro-Hyp — the primary structural repeat of collagen type I. Endogenous collagen matrikine fragment signaling fibroblast procollagen synthesis via TGF-β and integrin pathways. Well-characterized mechanism; no published topical clinical trials. Small size (~285 Da) makes it particularly suited to microneedling delivery.
Read the research →
How These Compounds Relate
This cluster does not have a single shared mechanism. It is a collection of compounds that converge on a common set of outcomes—improved skin appearance, wound healing, pigmentation, or anti-aging effects—through distinct and largely unrelated pathways. Collagen peptides provide substrate and fibroblast signaling. GHK-Cu drives matrix synthesis and remodeling. Argireline and leuphasyl reduce expression-line muscle activity. Afamelanotide and Melanotan II drive melanogenesis via MC1R. BPC-157 and TB-500 promote angiogenesis and cell migration. KPV and LL-37 suppress local inflammation.
The most important axis in this cluster is not mechanism—it is route of administration. GHK-Cu has legitimate human data in topical form. Argireline and matrixyl have human data in topical form. Collagen peptides have strong RCT data in oral form. The moment any of these compounds move into injectable use, the evidence base does not travel with them. This is not a minor caveat—it is the central interpretive challenge for this entire cluster, and it applies to multiple compounds here.
Afamelanotide and Melanotan II share an MC1R mechanism but differ in selectivity, approval status, and safety profile in ways that matter clinically. Afamelanotide is MC1R-selective, FDA-approved for a specific rare disease, and has a defined safety record. Melanotan II is non-selective across four melanocortin receptors, has never been approved, and carries a documented nevi-growth concern. They are not equivalent compounds with different approval luck—they are different compounds.
BPC-157 and TB-500 appear here as crossovers from the Injury Recovery cluster. Their skin applications are real and mechanistically grounded, but the evidence base for their use in dermatology specifically is thinner than the wound healing and connective tissue literature that earned them their primary cluster placement. They belong in this cluster for completeness and because community use warrants documentation—not because the skin evidence is strong.